{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["1999"],"condition":["Colorectal Adenoma","Adenoma"],"disease":["Colorectal Adenoma","Adenoma"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2025662"],"study_start_month":["12"],"keyword":["Rofecoxib"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)","description":"This study was to compare the effect of 156 weeks of treatment with MK-0966 (Rofecoxib) versus placebo on the recurrence of colorectal adenomas (growths that occur on the inside (the lining) of the large intestine, also known as the colon) in patients with a history of colorectal adenomas.","dates":{"creation":"1999-12-15"},"accession":"2025662","cross_references":{"ClinicalTrials___gov":["NCT00282386"]}}